Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rege

Showing results (961-970 of 1,003) with videos related to

Pageof 101
Sort By:
Nature Neuroscience|March 3, 2015
GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degenerationEthan A Winkler, Yoichiro Nishida, Abhay P Sagare, et al.
Nature Neuroscience|May 26, 2015
Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearanceZhen Zhao, Abhay P Sagare, Qingyi Ma, et al.
Leukemia|August 30, 2008
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phaseJ Cortes, D-W Kim, E Raffoux, et al.
Blood|October 3, 2009
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WPNicoletta Testoni, Giulia Marzocchi, Simona Luatti, et al.
Blood|February 14, 2015
Morgana acts as an oncosuppressor in chronic myeloid leukemiaAugusta Di Savino, Cristina Panuzzo, Stefania Rocca, et al.
Journal of Medicinal Chemistry|October 14, 2015
Novel Series of Dihydropyridinone P2X7 Receptor AntagonistsFrancisco Lopez-Tapia, Keith A M Walker, Christine Brotherton-Pleiss, et al.
Leukemia|October 3, 2002
Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemiaM Mancini, M L Vegna, G L Castoldi, et al.
Movement Disorders Clinical Practice|November 19, 2024
Preferences regarding Disclosure of Risk for Parkinson's Disease in a Population-based StudyPhilipp Mahlknecht, Simon Leiter, Corinne Horlings, et al.
Blood|March 7, 2009
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet StudyMichele Baccarani, Gianantonio Rosti, Fausto Castagnetti, et al.
Haematologica|April 7, 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 studyGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Pageof 101

Showing results (961-970 of 1,003) with videos related to

Sort By:
Pageof 101
Nature Neuroscience|March 3, 2015
GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degenerationEthan A Winkler, Yoichiro Nishida, Abhay P Sagare, et al.
Nature Neuroscience|May 26, 2015
Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearanceZhen Zhao, Abhay P Sagare, Qingyi Ma, et al.
Leukemia|August 30, 2008
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phaseJ Cortes, D-W Kim, E Raffoux, et al.
Blood|October 3, 2009
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WPNicoletta Testoni, Giulia Marzocchi, Simona Luatti, et al.
Blood|February 14, 2015
Morgana acts as an oncosuppressor in chronic myeloid leukemiaAugusta Di Savino, Cristina Panuzzo, Stefania Rocca, et al.
Journal of Medicinal Chemistry|October 14, 2015
Novel Series of Dihydropyridinone P2X7 Receptor AntagonistsFrancisco Lopez-Tapia, Keith A M Walker, Christine Brotherton-Pleiss, et al.
Leukemia|October 3, 2002
Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemiaM Mancini, M L Vegna, G L Castoldi, et al.
Movement Disorders Clinical Practice|November 19, 2024
Preferences regarding Disclosure of Risk for Parkinson's Disease in a Population-based StudyPhilipp Mahlknecht, Simon Leiter, Corinne Horlings, et al.
Blood|March 7, 2009
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet StudyMichele Baccarani, Gianantonio Rosti, Fausto Castagnetti, et al.
Haematologica|April 7, 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 studyGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Pageof 101